EUVIMEDEUVIMED entdecken
FallberichtScoping ReviewOpen Access · CC BY 4.0

Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review

Mengduan Pang iD, Ling Li iD, Qi Zhang iD, Min Zhao iD

Immunity, Inflammation and Disease · 2026

DOI: 10.1002/iid3.70515 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Immunity, Inflammation and Disease, 2026. Verfasst von Mengduan Pang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, First Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Janus Kinase Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.

Methods

We present a case of a 35‐year‐old male with refractory PsA who achieved significant clinical improvement through combination therapy with ixekizumab (an IL‐17 inhibitor) and upadacitinib (a JAK inhibitor), following inadequate responses to multiple monotherapies. A scoping review of the literature was conducted, analyzing studies on dual b/tsDMARD therapy in PsA.

Results

The patient achieved rapid clinical improvement with complete resolution of articular symptoms, normalization of inflammatory markers, and significant metabolic improvements. The scoping review identified 16 studies, highlighting the potential of multi‐target strategies while emphasizing safety concerns such as increased infection risks.

Conclusion

This case and review underscore the promise of combination therapy in PsA while emphasizing the need for further research to optimize its use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticInterleukin-17Janus Kinase InhibitorsAntibodies, Monoclonal, HumanizedHeterocyclic Compounds, 3-RingAntirheumatic AgentsHumansMaleAdultDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

IL‐17 inhibitorJAK inhibitorcase reportpsoriatic arthritisscoping review

Substanzen

Interleukin-17Janus Kinase InhibitorsixekizumabAntibodies, Monoclonal, HumanizedHeterocyclic Compounds, 3-RingupadacitinibAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, First Affiliated Hospital of Dalian Medical University, Dalian, China.

ORCID-Profile: Mengduan Pang, Ling Li, Qi Zhang, Min Zhao

Zitieren

APA

Pang, M., Li, L., Zhang, Q., & Zhao, M. (2026). Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70515

Vancouver

Pang M, Li L, Zhang Q, Zhao M. Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review. Immunity, Inflammation and Disease. 2026. doi:10.1002/iid3.70515

BibTeX
@article{Pang2026,
  author = {Pang, Mengduan and Li, Ling and Zhang, Qi and Zhao, Min},
  title = {Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  doi = {10.1002/iid3.70515}
}
Kostenlos starten →